- Home
- BRW vs MGTX Comparison
BRW vs MGTX Comparison
Compare BRW & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRW | MGTX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.6M | 610.1M |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BRW | MGTX |
|---|---|---|
| Price | $6.52 | $7.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | 214.9K | ★ 308.2K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,279,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $569.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 137.42 |
| 52 Week Low | $6.38 | $4.73 |
| 52 Week High | $8.49 | $9.73 |
Technical Indicators
Market Signals| Indicator | BRW | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.98 | 51.88 |
| Support Level | $6.41 | $7.23 |
| Resistance Level | $7.10 | $8.15 |
| Average True Range (ATR) | 0.08 | 0.37 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 52.12 | 75.29 |
Price Performance
Historical ComparisonAbout BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.